Dexrazoxane
Allergy to PEG e.Coli Asparaginase
Therapeutic Advances in Childhood Leukemia ConsortiumSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Allergy to PEG e.Coli Asparaginase cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ginkgo Biloba Extract Dongzhimen Hospital, Beijing | Phase 4 | BB |
Qinggongshoutao Bolus Dongzhimen Hospital, Beijing | Phase 4 | BB |
Thalidomide Chang Gung Memorial Hospital | Phase 2 | B |
(1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil 1:4 Chang Gung Memorial Hospital | Phase 2 | B |
Solu-Cortef University Medical Center Groningen | Phase 2 | CCC |
View all 17 →
Same molecule, other indications
Dexrazoxane is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
B
Indicative ·
59 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →